Auto-discovered from 1 recent study; not yet curated.
3 studies1 human2 review/other
Tracking 3 published studies of Tamoxifen: 1 in humans, 2 reviews/other.
Reported direction across studies: 1 mixed, 2 inconclusive.
These counts summarize what the studies reported; they are not a measure of whether Tamoxifen works.
ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11
Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.
Key findings
- The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
- Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
- Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
- PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
- For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMixed resultsModerate evidenceTier 3 · early human
Cancers · Sep 2020 · narrative review
This narrative review summarizes evidence that tamoxifen both increases the risk of endometrial cancer (estimated about 2–7 fold) and can have therapeutic activity in advanced or recurrent endometrial cancer with low toxicity. The authors discuss mechanistic explanations for these opposing effects, including tissue-specific ERα co-activator/co-repressor profiles and agonism at the membrane estrogen receptor GPER-1. The review does not present new primary data.
Reported effect: endometrial cancer risk (fold increase)
Key findings
- Tamoxifen is used for treatment and prevention of ER-positive breast cancer.
- Tamoxifen increases the risk of endometrial cancer by about 2-7 fold, and more aggressive types of EC with poor prognoses are observed in tamoxifen users.
- Tamoxifen can be an efficacious treatment for advanced or recurrent endometrial cancer with low toxicity.
- Differential agonist versus antagonist effects in endometrium are explained by tissue-specific expression of ERα co-activators and co-repressors and by tamoxifen acting as a pure agonist at GPER-1.
Limitations: Narrative review: no new primary data or pooled quantitative synthesis presented in the abstract.; Abstract does not state literature search or selection methods (potential selection bias).; Mechanistic explanations are proposed based on prior literature but not experimentally demonstrated within this article..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalSafetyInconclusiveLimited evidenceTier 3 · early humann = 21
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Jul 1995 · retrospective case series / archive review (single-center)
Tamoxifenuterine carcinosarcoma (malignant mixed Müllerian tumor)endometrial carcinosarcoma The authors report a cluster of five uterine carcinosarcoma cases in 1993 at their center, four of whom had been prescribed long-term tamoxifen for breast cancer. A review of archives from 1983-1992 found two additional tamoxifen-associated carcinosarcoma cases among 16 total cases. In total six patients with carcinosarcoma had been taking tamoxifen; five had been on the drug at least six years and one had a three-year history. The authors raise the question of a possible association between long-term tamoxifen use and development of endometrial carcinosarcoma.
Reported effects: 1993 cluster cases 5 · 1993 cluster tamoxifen-associated cases 4 · +5 more
Key findings
- A cluster of five patients with endometrial carcinosarcoma occurred at the center during 1993; four of these had been prescribed long-term tamoxifen for breast carcinoma.
- Archive review for 1983-1992 revealed two further cases of uterine carcinosarcoma occurring in patients prescribed tamoxifen, from a total of 16 cases of this tumor.
- Five of the six patients diagnosed with carcinosarcoma who had been taking tamoxifen had been maintained on the drug for at least 6 years; the other had a 3-year history of tamoxifen therapy.
- The authors raise the question of an association between long-term tamoxifen treatment and development of endometrial carcinosarcoma following increased prescribing after 1984.
Limitations: Small number of cases (cluster and a few archival cases).; Single-center, retrospective, descriptive case series without a control group or denominator of tamoxifen-exposed patients.; No statistical analysis or incidence rates provided to quantify risk.; Potential reporting and selection bias; confounding factors not addressed (e.g., underlying breast cancer population)..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Evidence at a glance: Tamoxifen by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.